[CAS NO. 1414854-42-4] Verosudil

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1414854-42-4]

Catalog

HY-16758

Brand

MCE

CAS

1414854-42-4

DESCRIPTION [1414854-42-4]

Overview

MDL	-
Molecular Weight	327.40
Molecular Formula	C17H17N3O2S
SMILES	O=C(NC1=CC2=C(C(NC=C2)=O)C=C1)C(N(C)C)C3=CSC=C3

For research use only. We do not sell to patients.

Summary

Verosudil (AR-12286) is a potent, selective Rho-kinase (ROCK) inhibitor with K _i s of 2 and 2 nM for ROCK1 and ROCK2 , respectively. AR-12286 lowers intraocular pressure (IOP) primarily by increasing aqueous humour outflow through the trabecular meshwork ^[1] ^[2] .

IC50 & Target

ROCK1

2 nM (Ki)

ROCK2

2 nM (Ki)

PKA

69 nM (Ki)

MRCKA

28 nM (Ki)

CAM2A

5855 nM (Ki)

PKC theta

9322 nM (Ki)

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01302249	Aerie Pharmaceuticals	Glaucoma\|Ocular Hypertension	February 2011	Phase 2
NCT01699464	Aerie Pharmaceuticals	Ocular Hypertension\|Open-angle Glaucoma	October 2012	Phase 2
NCT01474135	Aerie Pharmaceuticals	Glaucoma\|Ocular Hypertension	December 2011	Phase 2
NCT01789736	Aerie Pharmaceuticals	Open Angle Glaucoma\|Ocular Hypertension	February 2013	Phase 2
NCT00902200	Aerie Pharmaceuticals	Elevated Intraocular Pressure	May 2009	Phase 2
NCT01936389	Robert Ritch, MD, LLC.	Exfoliation Syndrome\|Ocular Hypertension\|Open Angle Glaucoma	September 2013	Phase 2
NCT01250197	Aerie Pharmaceuticals	Normal Volunteers	November 2010	Phase 1
NCT01330979	Aerie Pharmaceuticals	Open Angle Glaucoma\|Ocular Hypertension	May 2011	Phase 2
NCT02174991	New York Glaucoma Research Institute	Glaucoma	June 2014	Phase 2
NCT01060579	Aerie Pharmaceuticals	Glaucoma	February 2010	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL ( 50.92 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0544 mL	15.2718 mL	30.5437 mL
5 mM	0.6109 mL	3.0544 mL	6.1087 mL
10 mM	0.3054 mL	1.5272 mL	3.0544 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 1.67 mg/mL (5.10 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1.67 mg/mL (5.10 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 1.67 mg/mL (5.10 mM); Clear solution

* All of the co-solvents are available by MCE.